Mycophenolic acid (Synonyms: Mycophenolate)

Name: Mycophenolic acid
Brand: MedChemExpress
SKU: HY-B0421
Rating: 5.0 (14 reviews)

Cat. No.: HY-B0421 Purity: 99.94%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Mycophenolic acid is a potent uncompetitive inosine monophosphate dehydrogenase (IMPDH) inhibitor with an EC₅₀ of 0.24 µM. Mycophenolic acid demonstrates antiviral effects against a wide range of RNA viruses including influenza. Mycophenolic acid is an immunosuppressive agent. Antiangiogenic and antitumor effects.

For research use only. We do not sell to patients.

CAS No. : 24280-93-1

Size	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
100 mg	In-stock	Estimated Time of Arrival: December 31
500 mg	In-stock	Estimated Time of Arrival: December 31
1 g	In-stock	Estimated Time of Arrival: December 31
5 g	In-stock	Estimated Time of Arrival: December 31
10 g	Get quote
50 g	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 14 publication(s) in Google Scholar

Other Forms of Mycophenolic acid:

Mycophenolic acid-d₃ In-stock
Mycophenolic acid sodium In-stock
Mycophenolic acid (Standard) In-stock
(E/Z)-Mycophenolic Acid-¹³C,d₃ Get quote
Mycophenolic acid-¹³C₁₇ Get quote

14 Publications Citing Use of MCE Mycophenolic acid

Flow Cytometry

Cell Proliferation/Viability Assay

: Mycophenolic acid purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Nov 12;15(1):9515. [Abstract]; Mycophenolic acid (MPA) (0, 2.5, 7.5, 15 μM) treatment caused a dose-dependent increase of IMPDH2 protein levels.

: Mycophenolic acid purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Nov 12;15(1):9515. [Abstract]; Mycophenolic acid (MPA) (0, 2.5, 7.5, 15 μM) treatment reduced viability at the highest concentration used (15 μM).

: Mycophenolic acid purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Nov 12;15(1):9515. [Abstract]; HT-IF showed that there was a significant increase in ɣH2AX signal in Mycophenolic acid (MPA) treated cells already at 7.5 μM.

: Mycophenolic acid purchased from MedChemExpress. Usage Cited in: ACS Omega. 2025 Dec 8;10(50):62145-62156. [Abstract]; Dose response curves and % cell viability of mycophenolic acid (MPA) (10-100 μM) by MTT assay.

: Mycophenolic acid purchased from MedChemExpress. Usage Cited in: J Transl Med. 2024 Feb 3;22(1):133. [Abstract]; The apoptotic rate was analysed after Mycophenolic acid (MPA) and/or oxaliplatin treatment compared with that of untreated cells for 24 h by flow cytosmetry analysis in HCT8/L-OHP cells.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Endogenous Metabolite Isoform Specific Products:

View All Isoforms

Human Endogenous Metabolite Microbial Metabolite

View All Antibiotic Isoform Specific Products:

View All Isoforms

Aminoglycoside Glycopeptide Lipopeptide Macrolide Oxazolidinone Quinolone Tetracycline β-lactam

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target

Microbial Metabolite

Human Endogenous Metabolite

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	0.4 μM Compound: 1	In vitro antitumor activity against A549 human NSCLC lung carcinoma cells In vitro antitumor activity against A549 human NSCLC lung carcinoma cells	10.1016/0960-894X(95)00130-L
A549	IC₅₀	1.21 μM Compound: MPA; 1	Cytotoxicity against human A549 cells assessed as growth inhibition measured by SRB assay Cytotoxicity against human A549 cells assessed as growth inhibition measured by SRB assay	[PMID: 34044119]
BHK-21	CC₅₀	3.55 μM Compound: 61	cytotoxicity against golden hamster BHK-21 cells incubated for 72 hrs by MTT assay cytotoxicity against golden hamster BHK-21 cells incubated for 72 hrs by MTT assay	[PMID: 32845145]
BHK-21	CC₅₀	> 100 μM Compound: M 5255	Cytotoxicity against hamster BHK21 cells assessed as reduction in cell viability after 48 to 96 hrs by MTT assay Cytotoxicity against hamster BHK21 cells assessed as reduction in cell viability after 48 to 96 hrs by MTT assay	[PMID: 19482481]
BHK-21	CC₅₀	> 100 μM Compound: M 5255	Cytotoxicity against mock-infected BHK21 cells after 48 to 96 hrs by MTT assay Cytotoxicity against mock-infected BHK21 cells after 48 to 96 hrs by MTT assay	[PMID: 25082514]
BHK-21	EC₅₀	0.04 μM Compound: Mycophenolic acid	Inhibition of West Nile virus VLP replicon in BHK21 cell line Inhibition of West Nile virus VLP replicon in BHK21 cell line	[PMID: 16539402]
BHK-21	EC₅₀	1.4 μM Compound: Mycophenolic acid	Inhibition of West Nile viral Rluc-Neo-Rep in BHK21 cell line Inhibition of West Nile viral Rluc-Neo-Rep in BHK21 cell line	[PMID: 16539402]
BHK-21	EC₅₀	> 100 μM Compound: M 5255	Antiviral activity against Reovirus-1 infected in BHK-21 cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by MTT assay Antiviral activity against Reovirus-1 infected in BHK-21 cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by MTT assay	[PMID: 19482481]
BHK-21	EC₅₀	> 100 μM Compound: M 5255	Antiviral activity against Yellow fever virus infected in BHK-21 cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by MTT assay Antiviral activity against Yellow fever virus infected in BHK-21 cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by MTT assay	[PMID: 19482481]
BHK-21	EC₅₀	> 100 μM Compound: M 5255	Antiviral activity against Reovirus type-1 infected in BHK21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay Antiviral activity against Reovirus type-1 infected in BHK21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay	[PMID: 25082514]
BHK-21	EC₅₀	> 100 μM Compound: M 5255	Antiviral activity against Yellow fever virus infected in BHK21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay Antiviral activity against Yellow fever virus infected in BHK21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay	[PMID: 25082514]
BHK-21	EC₅₀	> 100 μM Compound: M5255	Antiviral activity against Reo-1 virus infected in BHK-21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay Antiviral activity against Reo-1 virus infected in BHK-21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay	[PMID: 26443549]
BHK-21	EC₅₀	> 100 μM Compound: M5255	Antiviral activity against YFV infected in BHK-21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay Antiviral activity against YFV infected in BHK-21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay	[PMID: 26443549]
CCRF-CEM	IC₅₀	0.34 μM Compound: MPA	In vitro secondary T-cell (CEM) proliferation assay In vitro secondary T-cell (CEM) proliferation assay	[PMID: 12014950]
CCRF-CEM	IC₅₀	0.39 μM Compound: MPA	Inhibitory activity against human T-lymphoblast CEM cell line using T cell proliferation assay Inhibitory activity against human T-lymphoblast CEM cell line using T cell proliferation assay	[PMID: 12127522]
CCRF-CEM	IC₅₀	0.39 μM Compound: MPA	The human T-lymphoblastCEM cell (ATCC) proliferation inhibitory activity was determined The human T-lymphoblastCEM cell (ATCC) proliferation inhibitory activity was determined	[PMID: 12270168]
CCRF-CEM	IC₅₀	0.39 μM Compound: MPA	Inhibitory concentration against human T-lymphoblast CEM cell line (ATCC) by CEM proliferation assay. Inhibitory concentration against human T-lymphoblast CEM cell line (ATCC) by CEM proliferation assay.	[PMID: 12270177]
CCRF-CEM	IC₅₀	0.39 μM Compound: MPA	Inhibitory activity against CEM cell proliferation Inhibitory activity against CEM cell proliferation	[PMID: 12565968]
CCRF-CEM	IC₅₀	0.39 μM Compound: MPA	Inhibitory activity against proliferation of CEM cell line Inhibitory activity against proliferation of CEM cell line	[PMID: 12565969]
CCRF-CEM	IC₅₀	0.54 μM Compound: MPA	Inhibition of CEM cell proliferation Inhibition of CEM cell proliferation	[PMID: 17585753]
CCRF-CEM	IC₅₀	0.9 μM Compound: 1	Cytotoxic activity against HIV uninfected T4 lymphocytes (CEM cell line) Cytotoxic activity against HIV uninfected T4 lymphocytes (CEM cell line)	10.1016/0960-894X(95)00130-L
CCRF-CEM	IC₅₀	340 nM Compound: MPA	Inhibition of CEM (human leukemia) cell proliferation. Inhibition of CEM (human leukemia) cell proliferation.	[PMID: 14505670]
CCRF-CEM	IC₅₀	> 156 μM Compound: 1, MPA	Antiproliferative activity against human CCRF-CEM cells after 48 hrs by MTT assay Antiproliferative activity against human CCRF-CEM cells after 48 hrs by MTT assay	[PMID: 22621840]
DU-145	IC₅₀	2.94 μM Compound: MPA	Cytotoxicity against human DU145 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human DU145 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 30223117]
FaDu	IC₅₀	6.72 μM Compound: MPA; 1	Cytotoxicity against human FaDu cells assessed as growth inhibition measured by SRB assay Cytotoxicity against human FaDu cells assessed as growth inhibition measured by SRB assay	[PMID: 34044119]
HL-60	IC₅₀	9.76 μM Compound: 1, MPA	Antiproliferative activity against human HL60 cells after 48 hrs by MTT assay Antiproliferative activity against human HL60 cells after 48 hrs by MTT assay	[PMID: 22621840]
HT-29	IC₅₀	0.4 μM Compound: Mycophenolic acid	Inhibitory activity of compound against HT-29 human colon adenocarcinoma cell line Inhibitory activity of compound against HT-29 human colon adenocarcinoma cell line	[PMID: 8568826]
HT-29	IC₅₀	0.9 μM Compound: 1	In vitro antitumor activity against HT-29 human colon adenocarcinoma cells In vitro antitumor activity against HT-29 human colon adenocarcinoma cells	10.1016/0960-894X(95)00130-L
HT-29	IC₅₀	6.48 μM Compound: MPA; 1	Cytotoxicity against human HT-29 cells assessed as growth inhibition measured by SRB assay Cytotoxicity against human HT-29 cells assessed as growth inhibition measured by SRB assay	[PMID: 34044119]
HUVEC	IC₅₀	99.2 nM Compound: MPA	Antiproliferative activity against HUVEC as measured by [3H]thymidine incorporation Antiproliferative activity against HUVEC as measured by [3H]thymidine incorporation	[PMID: 16640327]
HepG2	IC₅₀	1 μM Compound: 92125597	HARVARD: Inhibition of liver stage Plasmodium berghei infection in HepG2 cells HARVARD: Inhibition of liver stage Plasmodium berghei infection in HepG2 cells	[PMID: 22586124]
HepG2	IC₅₀	> 100 μM Compound: 92125597	HARVARD: Cytotoxicity in HepG2 cell line HARVARD: Cytotoxicity in HepG2 cell line	[PMID: 22586124]
Hepatocyte	EC₅₀	5.9 μM Compound: 1; MPA	Toxicity in human hepatocytes assessed by dehydrogenase activity measured after 48 hrs by CCK-8 assay Toxicity in human hepatocytes assessed by dehydrogenase activity measured after 48 hrs by CCK-8 assay	[PMID: 34055230]
Huh-7	CC₅₀	> 100 μM Compound: 1, MPA	Cytotoxicity against human Huh7.5 cells after 96 hrs by MTT assay Cytotoxicity against human Huh7.5 cells after 96 hrs by MTT assay	[PMID: 23999140]
Huh-7	IC₅₀	4.16 μM Compound: 1, MPA	Antiviral activity against HCV expressing pFL-J6/JFH/JC1 infected in human Huh7.5 cells assessed as inhibition of viral RNA synthesis after 96 hrs by one-step RT-PCR analysis Antiviral activity against HCV expressing pFL-J6/JFH/JC1 infected in human Huh7.5 cells assessed as inhibition of viral RNA synthesis after 96 hrs by one-step RT-PCR analysis	[PMID: 23999140]
Jurkat	EC₅₀	0.3 μM Compound: 1; MPA	Immunosuppression-mediated antiproliferative activity against human Jurkat T cells assessed as inhibition of cell growth incubated for 48 hrs by VPD450 staining based flow cytometry Immunosuppression-mediated antiproliferative activity against human Jurkat T cells assessed as inhibition of cell growth incubated for 48 hrs by VPD450 staining based flow cytometry	[PMID: 32007665]
Jurkat	EC₅₀	9.45 μM Compound: 1, MPA, Mycophenolic acid	Antiproliferative activity against human Jurkat cells assessed as incorporation of [3H]thymidine after 18 hrs by scintillation counting analysis Antiproliferative activity against human Jurkat cells assessed as incorporation of [3H]thymidine after 18 hrs by scintillation counting analysis	[PMID: 24121309]
Jurkat	IC₅₀	0.193 μM Compound: 1, MPA	Antiproliferative activity against human Jurkat cells after 48 hrs by MTT assay Antiproliferative activity against human Jurkat cells after 48 hrs by MTT assay	[PMID: 22621840]
Jurkat	IC₅₀	128 nM Compound: MPA	Antiproliferative activity against Jurkat T cells as measured by [3H]thymidine incorporation Antiproliferative activity against Jurkat T cells as measured by [3H]thymidine incorporation	[PMID: 16640327]
Jurkat	IC₅₀	28.21 μM Compound: 1, MPA, Mycophenolic acid	Cytotoxicity against human Jurkat cells after 48 hrs by MTT assay Cytotoxicity against human Jurkat cells after 48 hrs by MTT assay	[PMID: 24121309]
Jurkat	IC₅₀	60.6 μM Compound: 1; MPA	Immunosuppression-mediated cytotoxicity against human Jurkat T cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Immunosuppression-mediated cytotoxicity against human Jurkat T cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 32007665]
K562	IC₅₀	0.08 μM Compound: Mycophenolic acid (MPA)	Inhibitory activity against growth of human erythroleukemia K652 cells Inhibitory activity against growth of human erythroleukemia K652 cells	[PMID: 9484510]
K562	IC₅₀	0.19 μM Compound: 1, MPA	Cytotoxicity against human K562 cells after 72 hrs by trypan blue exclusion assay Cytotoxicity against human K562 cells after 72 hrs by trypan blue exclusion assay	[PMID: 20934342]
K562	IC₅₀	7.7 μM Compound: MPA	Antiproliferative activity against human K562 cells after 72 hrs Antiproliferative activity against human K562 cells after 72 hrs	[PMID: 17958343]
K562	IC₅₀	7.7 μM Compound: MPA	Antiproliferative activity against human K562 cells after 72 hrs by MTS assay Antiproliferative activity against human K562 cells after 72 hrs by MTS assay	[PMID: 18809333]
K562	IC₅₀	7.7 μM Compound: MPA	Antiproliferative activity against human K562 cells after 72 hrs by MTS assay Antiproliferative activity against human K562 cells after 72 hrs by MTS assay	[PMID: 21324702]
K562	IC₅₀	7.7 μM Compound: MPA, mycophenolic acid	Antiproliferative activity against human K562 cells after 72 hrs by MTS assay Antiproliferative activity against human K562 cells after 72 hrs by MTS assay	[PMID: 18038969]
L1210	IC₅₀	2.18 μM Compound: 1, MPA	Antiproliferative activity against mouse L1210 cells after 48 hrs by MTT assay Antiproliferative activity against mouse L1210 cells after 48 hrs by MTT assay	[PMID: 22621840]
L1210	IC₅₀	< 0.2 μM Compound: 1	In vitro antitumor activity against L1210 murine lymphocytic leukemia cells In vitro antitumor activity against L1210 murine lymphocytic leukemia cells	10.1016/0960-894X(95)00130-L
L1210	IC₅₀	< 0.2 μM Compound: Mycophenolic acid	Inhibitory activity of compound against L1210 leukemia cells in tissue culture Inhibitory activity of compound against L1210 leukemia cells in tissue culture	[PMID: 8568826]
LLC-MK2	CC₅₀	3.44 μM Compound: 61	Cytotoxicity against Rhesus macaque LLC-MK2 cells incubated for 72 hrs by MTT assay Cytotoxicity against Rhesus macaque LLC-MK2 cells incubated for 72 hrs by MTT assay	[PMID: 32845145]
MCF7	IC₅₀	0.5 μM Compound: 1	In vitro antitumor activity against MCF-7 human breast adenocarcinoma cells In vitro antitumor activity against MCF-7 human breast adenocarcinoma cells	10.1016/0960-894X(95)00130-L
MDA-MB-231	IC₅₀	4.38 μM Compound: MPA	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 30223117]
MDA-MB-231	IC₅₀	7.83 μM Compound: MPA; 1	Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition measured by SRB assay Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition measured by SRB assay	[PMID: 34044119]
MIN6	EC₅₀	0.6 μM Compound: 1; MPA	Toxicity in mouse MIN6 cells assessed by dehydrogenase activity measured after 48 hrs by CCK-8 assay Toxicity in mouse MIN6 cells assessed by dehydrogenase activity measured after 48 hrs by CCK-8 assay	[PMID: 34055230]
MOLT-4	IC₅₀	0.075 μM Compound: 1, MPA	Antiproliferative activity against human MOLT4 cells after 48 hrs by MTT assay Antiproliferative activity against human MOLT4 cells after 48 hrs by MTT assay	[PMID: 22621840]
MT4	CC₅₀	0.2 μM Compound: M 5255	Cytotoxicity against human MT4 cells after 96 hrs by MTT assay Cytotoxicity against human MT4 cells after 96 hrs by MTT assay	[PMID: 19482481]
MT4	CC₅₀	0.2 μM Compound: M 5255	Cytotoxicity against human MT4 cells after 96 hrs by MTT assay Cytotoxicity against human MT4 cells after 96 hrs by MTT assay	[PMID: 20359898]
MT4	CC₅₀	0.2 μM Compound: M 5255	Cytotoxicity against mock-infected human MT4 cells after 96 hrs by MTT assay Cytotoxicity against mock-infected human MT4 cells after 96 hrs by MTT assay	[PMID: 25082514]
MT4	CC₅₀	0.2 μM Compound: M5255	Cytotoxicity against human MT4 cells assessed as cell viability after 96 hrs by MTT assay Cytotoxicity against human MT4 cells assessed as cell viability after 96 hrs by MTT assay	[PMID: 26443549]
PBMC	EC₅₀	0.0301 μM Compound: 1; MPA	Immunosuppression-mediated antiproliferative activity against anti-CD3/anti-CD28-stimulated human PBMC cells assessed as inhibition of cell growth incubated for 72 hrs by VPD450 staining based flow cytometry Immunosuppression-mediated antiproliferative activity against anti-CD3/anti-CD28-stimulated human PBMC cells assessed as inhibition of cell growth incubated for 72 hrs by VPD450 staining based flow cytometry	[PMID: 32007665]
PBMC	EC₅₀	uM μM Compound: 1, MPA, Mycophenolic acid	Antiproliferative activity against human PBMC assessed as incorporation of [3H]thymidine after 18 hrs by scintillation counting analysis Antiproliferative activity against human PBMC assessed as incorporation of [3H]thymidine after 18 hrs by scintillation counting analysis	[PMID: 24121309]
PBMC	IC₅₀	0.044 μM Compound: 1, MPA, Mycophenolic acid	Cytotoxicity against human PBMC after 72 hrs by MTT assay Cytotoxicity against human PBMC after 72 hrs by MTT assay	[PMID: 24121309]
PBMC	IC₅₀	0.13 μM Compound: MPA	Inhibition of T cell proliferation in PBMC cells Inhibition of T cell proliferation in PBMC cells	[PMID: 17585753]
PBMC	IC₅₀	0.14 μM Compound: 1; MPA	Immunosuppression-mediated cytotoxicity against anti-CD3/anti-CD28-stimulated human PBMC cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Immunosuppression-mediated cytotoxicity against anti-CD3/anti-CD28-stimulated human PBMC cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 32007665]
PBMC	IC₅₀	0.18 μM Compound: Mycophenolic acid	Immunosuppressive activity in anti-CD3/anti-CD28-induced human PBMC after 96 hrs by flow cytometry Immunosuppressive activity in anti-CD3/anti-CD28-induced human PBMC after 96 hrs by flow cytometry	[PMID: 24963543]
PBMC	IC₅₀	1.28 μM Compound: 1, MPA	Antiproliferative activity against activated-human PBMC after 96 hrs by MTT assay Antiproliferative activity against activated-human PBMC after 96 hrs by MTT assay	[PMID: 22621840]
PBMC	IC₅₀	> 100 μM Compound: Mycophenolic acid	Cytotoxicity against human PBMC after 96 hrs by flow cytometry Cytotoxicity against human PBMC after 96 hrs by flow cytometry	[PMID: 24963543]
PSN1	IC₅₀	0.7 μM Compound: 1	In vitro antitumor activity against PSN-1 human pancreatic carcinoma cells In vitro antitumor activity against PSN-1 human pancreatic carcinoma cells	10.1016/0960-894X(95)00130-L
SH-SY5Y	IC₅₀	0.56 μM Compound: MPA; 1	Cytotoxicity against human SH-SY5Y cells assessed as growth inhibition measured by SRB assay Cytotoxicity against human SH-SY5Y cells assessed as growth inhibition measured by SRB assay	[PMID: 34044119]
T-cell	IC₅₀	0.28 μM Compound: MPA	Immunosuppressive activity in in mouse T-cells assessed as inhibition of concanavalin A-induced proliferation Immunosuppressive activity in in mouse T-cells assessed as inhibition of concanavalin A-induced proliferation	[PMID: 22172700]
T-cell	IC₅₀	0.32 μM Compound: 4, MPA	Immunosuppressive activity in C57BL/6 mouse T lymphocytes assessed as inhibition of cell proliferation after 72 hrs by MTT assay Immunosuppressive activity in C57BL/6 mouse T lymphocytes assessed as inhibition of cell proliferation after 72 hrs by MTT assay	[PMID: 22464133]
U-87MG ATCC	IC₅₀	10.69 μM Compound: MPA	Cytotoxicity against human U87MG cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human U87MG cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 30223117]
VSMC	IC₅₀	1 μM Compound: MPA, mycophenolic acid	Antiproliferative activity against PDGF-induced rat aortic VSMC by colorimetric assay Antiproliferative activity against PDGF-induced rat aortic VSMC by colorimetric assay	[PMID: 18400498]
Vero	CC₅₀	18.7 μM Compound: Mycophenolic acid	Cytotoxicity activity against African green monkey Vero cells assessed as reduction in cell viability by MTT assay Cytotoxicity activity against African green monkey Vero cells assessed as reduction in cell viability by MTT assay	[PMID: 32786878]
Vero	CC₅₀	30 μM Compound: 138; MAP	Cytotoxicity against African green monkey Vero cells by neutral red dye uptake assay Cytotoxicity against African green monkey Vero cells by neutral red dye uptake assay	[PMID: 28689975]
Vero	CC₅₀	624.34 μM Compound: 1, MPA	Cytotoxicity against african green monkey Vero cells after 96 hrs by MTT assay Cytotoxicity against african green monkey Vero cells after 96 hrs by MTT assay	[PMID: 23999140]
Vero	CC₅₀	>= 12.5 μM Compound: MA	Cytotoxicity against african green monkey Vero 76 cells after 48 to 96 hrs by crystal violet staining Cytotoxicity against african green monkey Vero 76 cells after 48 to 96 hrs by crystal violet staining	[PMID: 22047799]
Vero	CC₅₀	>= 12.5 μM Compound: Mycophenolic acid	Cytotoxicity against african green monkey Vero 76 cells after 48 to 96 hrs by MTT assay Cytotoxicity against african green monkey Vero 76 cells after 48 to 96 hrs by MTT assay	[PMID: 22513121]
Vero	CC₅₀	>= 13 μM Compound: M 5255	Cytotoxicity against african green monkey Vero 76 cells by crystal violet staining Cytotoxicity against african green monkey Vero 76 cells by crystal violet staining	[PMID: 19482481]
Vero	CC₅₀	>= 13 μM Compound: M 5255	Cytotoxicity against african green monkey Vero cells Cytotoxicity against african green monkey Vero cells	[PMID: 20359898]
Vero	EC₅₀	0.04 μM Compound: Mycophenolic acid	Inhibition of Rluc-FL-WNV replicon in Vero cells Inhibition of Rluc-FL-WNV replicon in Vero cells	[PMID: 16539402]
Vero	EC₅₀	0.08 μM Compound: Mycophenolic acid	Inhibition of West Nile viral Rluc-Neo-Rep in Vero cells Inhibition of West Nile viral Rluc-Neo-Rep in Vero cells	[PMID: 16539402]
Vero	EC₅₀	0.4 μM Compound: Mycophenolic acid	Antiviral activity against para influenza 3 virus infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis Antiviral activity against para influenza 3 virus infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis	[PMID: 28477572]
Vero	EC₅₀	0.6 μM Compound: M 5255	Antiviral activity against RSV A2 infected in african green monkey Vero cells after 5 days by plaque reduction assay Antiviral activity against RSV A2 infected in african green monkey Vero cells after 5 days by plaque reduction assay	[PMID: 20359898]
Vero	EC₅₀	0.6 μM Compound: M 5255	Antiviral activity against Respiratory syncytial virus infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 5 days by plaque reduction assay Antiviral activity against Respiratory syncytial virus infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 5 days by plaque reduction assay	[PMID: 25082514]
Vero	EC₅₀	0.8 μM Compound: MPA	Antiviral activity against Para-influenza-3 virus infected in African green monkey Vero cells assessed as protection against virus-induced cytopathic effect measured after 3 to 5 days by microscopic analysis Antiviral activity against Para-influenza-3 virus infected in African green monkey Vero cells assessed as protection against virus-induced cytopathic effect measured after 3 to 5 days by microscopic analysis	[PMID: 27979594]
Vero	EC₅₀	1.4 μM Compound: Mycophenolic acid	Antiviral activity against Sindbis virus infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis Antiviral activity against Sindbis virus infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis	[PMID: 28477572]
Vero	EC₅₀	1.5 μM Compound: M5255	Antiviral activity against Vaccinia virus infected in African green monkey Vero 76 cells after 3 days by plaque reduction assay Antiviral activity against Vaccinia virus infected in African green monkey Vero 76 cells after 3 days by plaque reduction assay	[PMID: 25913116]
Vero	EC₅₀	1.5 μM Compound: MA	Antiviral activity against Vaccinia virus Lister Elstree infected in african green monkey Vero 76 cells assessed as reduction of virus-induced plaque formation after 3 days using crystal violet staining Antiviral activity against Vaccinia virus Lister Elstree infected in african green monkey Vero 76 cells assessed as reduction of virus-induced plaque formation after 3 days using crystal violet staining	[PMID: 22047799]
Vero	EC₅₀	1.5 μM Compound: Mycophenolic acid	Antiviral activity against Human Vaccinia virus ATCC VR-1549 infected in African green monkey Vero 76 cells assessed as reduction of virus-plaque formation after 3 days by crystal violet staining Antiviral activity against Human Vaccinia virus ATCC VR-1549 infected in African green monkey Vero 76 cells assessed as reduction of virus-plaque formation after 3 days by crystal violet staining	[PMID: 26119992]
Vero	EC₅₀	1.8 μM Compound: M5255	Antiviral activity against Vaccinia virus infected African green monkey Vero 76 cells assessed as reduction in plaque number treated after viral infection measured after 3 days by plaque reduction assay Antiviral activity against Vaccinia virus infected African green monkey Vero 76 cells assessed as reduction in plaque number treated after viral infection measured after 3 days by plaque reduction assay	10.1007/s00044-012-0342-1
Vero	EC₅₀	1.8 μM Compound: MPA	Antiviral activity against Reovirus-1 infected in African green monkey Vero cells assessed as protection against virus-induced cytopathic effect measured after 3 to 5 days by microscopic analysis Antiviral activity against Reovirus-1 infected in African green monkey Vero cells assessed as protection against virus-induced cytopathic effect measured after 3 to 5 days by microscopic analysis	[PMID: 27979594]
Vero	EC₅₀	1.8 μM Compound: Mycophenolic acid	Antiviral activity against Reovirus 1 infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis Antiviral activity against Reovirus 1 infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis	[PMID: 28477572]
Vero	EC₅₀	2 μM Compound: M 5255	Antiviral activity against Vaccinia Virus infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 3 days by plaque reduction assay Antiviral activity against Vaccinia Virus infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 3 days by plaque reduction assay	[PMID: 25082514]
Vero	EC₅₀	2.3 μM Compound: Mycophenolic acid	Antiviral activity against Yellow fever virus infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis Antiviral activity against Yellow fever virus infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis	[PMID: 28477572]
Vero	EC₅₀	20 μM Compound: MPA	Antiviral activity against Punta Toro virus infected in African green monkey Vero cells assessed as protection against virus-induced cytopathic effect measured after 3 to 5 days by microscopic analysis Antiviral activity against Punta Toro virus infected in African green monkey Vero cells assessed as protection against virus-induced cytopathic effect measured after 3 to 5 days by microscopic analysis	[PMID: 27979594]
Vero	EC₅₀	20 μM Compound: Mycophenolic acid	Antiviral activity against Punta Toro virus infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis Antiviral activity against Punta Toro virus infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis	[PMID: 28477572]
Vero	EC₅₀	4 μM Compound: MPA	Antiviral activity against Sindbis virus infected in African green monkey Vero cells assessed as protection against virus-induced cytopathic effect measured after 3 to 5 days by microscopic analysis Antiviral activity against Sindbis virus infected in African green monkey Vero cells assessed as protection against virus-induced cytopathic effect measured after 3 to 5 days by microscopic analysis	[PMID: 27979594]
Vero	EC₅₀	4 μM Compound: MPA	Antiviral activity against Yellow fever virus infected in African green monkey Vero cells assessed as protection against virus-induced cytopathic effect measured after 3 to 5 days by microscopic analysis Antiviral activity against Yellow fever virus infected in African green monkey Vero cells assessed as protection against virus-induced cytopathic effect measured after 3 to 5 days by microscopic analysis	[PMID: 27979594]
Vero	EC₅₀	5.7 μM Compound: MPA, Mycophenolic acid	Antiviral activity against Dengue virus 2 NGC infected in african green monkey Vero cells after 3 days by immunofluorescence assay Antiviral activity against Dengue virus 2 NGC infected in african green monkey Vero cells after 3 days by immunofluorescence assay	[PMID: 17360676]
Vero	EC₅₀	> 100 μM Compound: M 5255	Antiviral activity against Coxsackievirus B5 infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 3 days by plaque reduction assay Antiviral activity against Coxsackievirus B5 infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 3 days by plaque reduction assay	[PMID: 25082514]
Vero	EC₅₀	> 100 μM Compound: M 5255	Antiviral activity against HSV1 infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 3 days by plaque reduction assay Antiviral activity against HSV1 infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 3 days by plaque reduction assay	[PMID: 25082514]
Vero	EC₅₀	> 100 μM Compound: M 5255	Antiviral activity against Poliovirus type 1 Sabin strain infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 2 days by plaque reduction assay Antiviral activity against Poliovirus type 1 Sabin strain infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 2 days by plaque reduction assay	[PMID: 25082514]
Vero	EC₅₀	> 100 μM Compound: Mycophenolic acid	Antiviral activity against Coxsackie B4 virus infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis Antiviral activity against Coxsackie B4 virus infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis	[PMID: 28477572]
Vero	EC₅₀	> 13 μM Compound: M 5255	Antiviral activity against HSV1 KOS infected in african green monkey Vero cells after 3 days by plaque reduction assay Antiviral activity against HSV1 KOS infected in african green monkey Vero cells after 3 days by plaque reduction assay	[PMID: 20359898]
Vero	EC₅₀	> 13 μM Compound: M 5255	Antiviral activity against Human coxsackievirus B2 Ohio-1 infected in african green monkey Vero cells after 3 days by plaque reduction assay Antiviral activity against Human coxsackievirus B2 Ohio-1 infected in african green monkey Vero cells after 3 days by plaque reduction assay	[PMID: 20359898]
Vero	EC₅₀	> 13 μM Compound: M 5255	Antiviral activity against Polio virus type1 Sabin strain Chat infected in african green monkey Vero cells after 2 days by plaque reduction assay Antiviral activity against Polio virus type1 Sabin strain Chat infected in african green monkey Vero cells after 2 days by plaque reduction assay	[PMID: 20359898]
Vero	EC₅₀	> 250 μM Compound: MPA	Antiviral activity against Coxsackie virus B4 infected in African green monkey Vero cells assessed as protection against virus-induced cytopathic effect measured after 3 to 5 days by microscopic analysis Antiviral activity against Coxsackie virus B4 infected in African green monkey Vero cells assessed as protection against virus-induced cytopathic effect measured after 3 to 5 days by microscopic analysis	[PMID: 27979594]
Vero	IC₅₀	10.15 μM Compound: 1, MPA	Antiviral activity against Coxsackie B3 virus Nancy in african green monkey Vero cells assessed as inhibition virus-induced cytopathic effect after 48 hrs Antiviral activity against Coxsackie B3 virus Nancy in african green monkey Vero cells assessed as inhibition virus-induced cytopathic effect after 48 hrs	[PMID: 23999140]
Vero	IC₅₀	69.36 μM Compound: 1, MPA	Antiviral activity against Coxsackie B6 virus Schmitt in african green monkey Vero cells assessed as inhibition virus-induced cytopathic effect after 48 hrs Antiviral activity against Coxsackie B6 virus Schmitt in african green monkey Vero cells assessed as inhibition virus-induced cytopathic effect after 48 hrs	[PMID: 23999140]
Vero 76	CC₅₀	19 μM Compound: M5255	Cytotoxicity against African green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by MTT method Cytotoxicity against African green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by MTT method	[PMID: 25913116]
Vero 76	CC₅₀	20 μM Compound: M 5255	Cytotoxicity against mock-infected african green monkey Vero 76 cells after 48 to 96 hrs by MTT assay Cytotoxicity against mock-infected african green monkey Vero 76 cells after 48 to 96 hrs by MTT assay	[PMID: 25082514]
Vero 76	CC₅₀	20 μM Compound: M5255	Cytotoxicity against african green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by crystal violet staining method Cytotoxicity against african green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by crystal violet staining method	[PMID: 26443549]
Vero 76	CC₅₀	9 μM Compound: M5255	Cytotoxicity against African green monkey Vero 76 cells assessed as decrease in cell viability after 48 to 96 hrs by MTT assay Cytotoxicity against African green monkey Vero 76 cells assessed as decrease in cell viability after 48 to 96 hrs by MTT assay	[PMID: 29028528]
Vero 76	CC₅₀	> 100 μM Compound: Mycophenolic acid	Cytotoxicity against African green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by crystal violet staining Cytotoxicity against African green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by crystal violet staining	[PMID: 26119992]
Vero 76	CC₅₀	> 12.5 μM Compound: MA	Cytotoxicity against mock-infected african green monkey Vero 76 cells assessed as reduction in cell viability after 48 to 96 hrs by MTT assay Cytotoxicity against mock-infected african green monkey Vero 76 cells assessed as reduction in cell viability after 48 to 96 hrs by MTT assay	[PMID: 27161176]
Vero 76	EC₅₀	0.6 μM Compound: M 5255	Antiviral activity against Respiratory syncytial virus A2 infected in Vero-76 cells after 5 days by plaque reduction assay Antiviral activity against Respiratory syncytial virus A2 infected in Vero-76 cells after 5 days by plaque reduction assay	[PMID: 19482481]
Vero 76	EC₅₀	0.6 μM Compound: M5255	Antiviral activity against human RSV infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by plaque reduction assay Antiviral activity against human RSV infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by plaque reduction assay	[PMID: 26443549]
Vero 76	EC₅₀	1.5 μM Compound: Mycophenolic acid	Antiviral activity against Vaccinia virus Elstree-Lister ATCC VR-1549 infected in african green monkey Vero-76 cells assessed as reduction in viral plaque after 3 days by crystal violet staining Antiviral activity against Vaccinia virus Elstree-Lister ATCC VR-1549 infected in african green monkey Vero-76 cells assessed as reduction in viral plaque after 3 days by crystal violet staining	[PMID: 22513121]
Vero 76	EC₅₀	1.8 μM Compound: M 5255	Antiviral activity against Vaccinia virus infected African green monkey Vero76 cells assessed as reduction of virus-induced plaque reduction after 3 days by MTT assay Antiviral activity against Vaccinia virus infected African green monkey Vero76 cells assessed as reduction of virus-induced plaque reduction after 3 days by MTT assay	10.1007/s00044-010-9513-0
Vero 76	EC₅₀	> 100 μM Compound: M5255	Antiviral activity against Human poliovirus 1 Sabin infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity by plaque reduction assay Antiviral activity against Human poliovirus 1 Sabin infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity by plaque reduction assay	[PMID: 26443549]
Vero 76	EC₅₀	> 100 μM Compound: M5255	Antiviral activity against human CVB5 infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity after 3 days by plaque reduction assay Antiviral activity against human CVB5 infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity after 3 days by plaque reduction assay	[PMID: 26443549]
Vero 76	EC₅₀	> 13 μM Compound: M 5255	Antiviral activity against Coxsackie virus type B2 virus infected in african green monkey Vero-76 cells after 3 days by plaque reduction assay Antiviral activity against Coxsackie virus type B2 virus infected in african green monkey Vero-76 cells after 3 days by plaque reduction assay	[PMID: 19482481]
Vero 76	EC₅₀	> 13 μM Compound: M 5255	Antiviral activity against HSV1 infected in Vero-76 cells after 3 days by plaque reduction assay Antiviral activity against HSV1 infected in Vero-76 cells after 3 days by plaque reduction assay	[PMID: 19482481]

In Vitro

Mycophenolic acid demonstrates antiviral effects against a wide range of RNA viruses including influenza, dengue virus, Zika virus, rotavirus, CCHFV, and hantavirus^[1].
IMPDH is the rate-limiting enzyme in the de novo synthesis of guanosine nucleotides^[2].
Mycophenolic acid (0.01-1 μM; 72 hours) exhibits preferential antiproliferative activity against the endothelial cells and fibroblasts. Endothelial cells are most sensitive cells to Mycophenolic acid treatment with an IC₅₀ <500 nM for antimitotic effects^[2].
Fibroblasts are also prone to Mycophenolic acid-induced cell cycle inhibition but exhibit a higher IC₅₀ (<1 μM) compared with endothelial cells. The two human tumor cell lines A549 non-small cell lung cancer cells and PC3 prostate cancer cells show intermediate sensitivity with an IC₅₀ >1 μM. U87 glioblastoma cells are resistant against MPA treatment up to 1 μM^[2].
Mycophenolic acid (0.05-2 μM; 18 hours) exhibits a dose-dependent down-regulation of HDAC2 and MYC, whereas up-regulates NDRG1^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[2]

Cell Line:	Primary isolated human dermal microvascular endothelial cells (HDMVEC) , fibroblasts, U87 glioblastoma cells, PC3 prostate cancer cells, A549 non-small cell lung cancer cells
Concentration:	0.01, 0.1, 1 μM
Incubation Time:	72 hours
Result:	Exhibited preferential antiproliferative activity against HDMVEC and fibroblasts. Whereas U87 glioblastoma cells were resistant to treatment, A549 non-small cell lung cancer and PC3 prostate cancer cells showed intermediate sensitivity.

Western Blot Analysis^[2]

Cell Line:	HDMVEC
Concentration:	0, 0.05, 0.1, 0.5, 1, and 2 μM
Incubation Time:	18 hours
Result:	Showed a dose-dependent regulation of HDAC2, MYC, and NDRG1.

In Vivo

Mycophenolic acid exerts its antitumor effects via modulation of the tumor microenvironment, U87 tumor growth is markedly inhibited in vivo in BALB/c nude mice^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Athymic 8-week-old, 20 g BALB/c nu/nu mice bearing Mycophenolic acid-resistant human U87 tumor model^[2]
Dosage:	120 mg/kg MMF (the morpholinoethyl ester prodrug of Mycophenolic acid)
Administration:	Oral gavage; b.i.d.
Result:	MMF (the morpholinoethyl ester prodrug of Mycophenolic acid) significantly inhibited tumor growth (∼70% after day 14 after tumor implantation) in MMF-treated versus control mice. Microvessel density (CD31 staining) and pericyte coverage determined by α-smooth muscle actin staining were markedly reduced in MMF-treated versus control tumors (44% and 78%, respectively).

Molecular Weight

320.34

Formula

C₁₇H₂₀O₆

CAS No.

24280-93-1

Appearance

Solid

Color

White to off-white

SMILES

O=C(O)CC/C(C)=C/CC1=C(O)C2=C(COC2=O)C(C)=C1OC

Structure Classification

Ketones, Aldehydes, Acids

Initial Source

Microorganisms

Endogenous metabolite

several species of Penicillium

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Solvent & Solubility

In Vitro:

DMSO : ≥ 100 mg/mL (312.17 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : < 0.1 mg/mL (insoluble)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.1217 mL	15.6084 mL	31.2168 mL
5 mM	0.6243 mL	3.1217 mL	6.2434 mL
10 mM	0.3122 mL	1.5608 mL	3.1217 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (7.80 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (7.80 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (7.80 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: Corn Oil
Solubility: 33.33 mg/mL (104.05 mM); Suspended solution; Need ultrasonic and warming and heat to 60°C

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.94%

Select Batch:

Data Sheet (279 KB) SDS (537 KB)

COA (247 KB) HNMR (266 KB) LCMS (94 KB)

Handling Instructions (2659 KB)

References

[1]. Stephen R Welch, et al. Screening and Identification of Lujo Virus Inhibitors Using a Recombinant Reporter Virus Platform. Viruses. 2021 Jun 28;13(7):1255. [Content Brief]

[2]. Sophie Domhan, et al. Molecular mechanisms of the antiangiogenic and antitumor effects of mycophenolic acid. Mol Cancer Ther. 2008 Jun;7(6):1656-68. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	3.1217 mL	15.6084 mL	31.2168 mL	78.0421 mL
	5 mM	0.6243 mL	3.1217 mL	6.2434 mL	15.6084 mL
	10 mM	0.3122 mL	1.5608 mL	3.1217 mL	7.8042 mL
	15 mM	0.2081 mL	1.0406 mL	2.0811 mL	5.2028 mL
	20 mM	0.1561 mL	0.7804 mL	1.5608 mL	3.9021 mL
	25 mM	0.1249 mL	0.6243 mL	1.2487 mL	3.1217 mL
	30 mM	0.1041 mL	0.5203 mL	1.0406 mL	2.6014 mL
	40 mM	0.0780 mL	0.3902 mL	0.7804 mL	1.9511 mL
	50 mM	0.0624 mL	0.3122 mL	0.6243 mL	1.5608 mL
	60 mM	0.0520 mL	0.2601 mL	0.5203 mL	1.3007 mL
	80 mM	0.0390 mL	0.1951 mL	0.3902 mL	0.9755 mL
	100 mM	0.0312 mL	0.1561 mL	0.3122 mL	0.7804 mL

Mycophenolic acid Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Product Name			Requested Quantity *
Applicant Name *			Salutation
Email Address *			Phone Number *
Department			Organization Name *
City			State
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Mycophenolic acid (Synonyms: Mycophenolate)

Customer Review

Other Forms of Mycophenolic acid:

14 Publications Citing Use of MCE Mycophenolic acid

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Endogenous Metabolite Isoform Specific Products:

View All Antibiotic Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Mycophenolic acid Related Classifications

Keywords:

Your Recently Viewed Products:

Mycophenolic acid (Synonyms: Mycophenolate)

Customer Review

Other Forms of Mycophenolic acid:

Mycophenolic acid Related Antibodies

14 Publications Citing Use of MCE Mycophenolic acid

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Endogenous Metabolite Isoform Specific Products:

View All Antibiotic Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Mycophenolic acid Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Mycophenolic acid Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report